Angi Appoints Michael Steib as CEO, Signaling Shift from Turnaround to Growth

What happened

Angi announced the appointment of Michael Steib as its new CEO, replacing the previous chief executive as the company transitions from a cost-focused turnaround to a growth-oriented strategy. Steib's background in scaling consumer marketplaces aligns with Angi's goal of returning to mid-single-digit revenue growth by 2026, but the company faces structural headwinds including a 10% year-over-year revenue decline in Q3 2025. Management has been aggressively cutting costs—including a 350-person layoff in January 2026—while nearly doubling TV advertising spend to stimulate demand, yet proprietary lead growth has not offset network volume collapse. The CEO change may inject fresh strategic thinking, but it also introduces execution uncertainty as Steib assesses the business and potentially reallocates resources. The announcement does not immediately resolve the core challenge of stabilizing total revenue, which remains the key metric for the investment thesis.

Implication

Investors should interpret the CEO appointment as a signal that the board is prioritizing growth over further cost-cutting, which could lead to higher marketing and technology spend and near-term margin pressure. Steib's strategic priorities and execution will be critical in determining whether Angi can reverse its revenue decline and accelerate proprietary volumes. However, with $500 million of debt maturing in 2028 and an aggressive buyback program, a shift toward growth investment could strain free cash flow if demand does not improve. We will monitor for changes in guidance, marketing intensity, and capital allocation under the new leadership, as these will provide early clues on the direction of the turnaround. Until total revenue shows a clear inflection, we maintain a WAIT rating and recommend investors focus on the next few quarterly reports to assess execution.

Thesis delta

The appointment of Michael Steib introduces a potential growth-oriented catalyst, but it does not alter our fundamental view that Angi's revenue decline must reverse before we become constructive. We will watch whether Steib accelerates proprietary growth and improves marketplace quality while maintaining the cost discipline that has supported profitability. Our WAIT rating remains, with a re-assessment window of 12-18 months as we look for evidence of sustained revenue growth and free cash flow strength.